GTF2C2: A Potential Drug Target and Biomarker for Cancer (G2976)

Target Name: GTF3C2

NCBI ID: G2976

GTF3C2

GTF2C2: A Potential Drug Target and Biomarker for Cancer

Gene transcription factor IIIC (GTF3C2) is a protein that plays a crucial role in the regulation of gene expression in various organisms, including humans. GTF3C2 is a subunit of the GTF2 transcription factor, which is a protein that binds to specific DNA sequences to regulate gene expression. GTF2C2 is composed of three subunits, including the GTF2C2 alpha subunit, the GTF2C2 beta subunit, and the GTF2C2 gamma subunit.

The GTF2C2 subunit is a 110 kDa protein that contains 255 amino acid residues. It is characterized by a variety of unique features, including a N-terminal alpha helix, a C-terminal domain that includes a putative nuclear localization domain, and a unique N -end that is rich in electrostatic potential.

Function

GTF2C2 is a key transcription factor that is involved in the regulation of various gene expression pathways, including cell growth, differentiation, and apoptosis. It has been shown to play a role in the regulation of cell cycle progression, and is often used as a drug target in cancer research.

One of the key functions of GTF2C2 is its ability to bind to specific DNA sequences with high affinity. This is accomplished through its unique N-end domain, which is rich in electrostatic potential and is able to interact with DNA in a specific way. interaction allows GTF2C2 to bind to its target DNA sequences with high affinity, enabling it to efficiently regulate gene expression.

Another important function of GTF2C2 is its ability to form a complex with other transcription factors, including GTF2C2 alpha and GTF2C2 gamma. This complex is able to enhance the transcriptional activity of these transcription factors, allowing them to bind to DNA with greater affinity and promote gene expression.

Drug targeting

GTF2C2 has been identified as a potential drug target in cancer research, due to its involvement in the regulation of gene expression and its ability to interact with other transcription factors. Several studies have shown that inhibiting the activity of GTF2C2 can lead to a reduction in the expression of genes involved in cell growth, differentiation, and apoptosis, which can be a useful therapeutic approach in cancer treatment.

In addition to its potential therapeutic uses, GTF2C2 has also been shown to be a useful biomarker in cancer research. The expression of GTF2C2 has been shown to be elevated in various types of cancer, including breast, lung, and colorectal cancer. This suggests that GTF2C2 may be a useful biomarker for the diagnosis and prognosis of cancer.

Conclusion

GTF2C2 is a protein that plays a crucial role in the regulation of gene expression and has been shown to be involved in the regulation of various cellular processes. Its unique N-end domain, which is rich in electrostatic potential, allows it to bind to specific DNA sequences with high affinity and form a complex with other transcription factors. As a result, GTF2C2 has been identified as a potential drug target in cancer research and as a useful biomarker for the diagnosis and prognosis of cancer. Further research is needed to fully understand the role of GTF2C2 in gene expression and its potential as a therapeutic agent.

Protein Name: General Transcription Factor IIIC Subunit 2

Functions: Required for RNA polymerase III-mediated transcription. Component of TFIIIC that initiates transcription complex assembly on tRNA and is required for transcription of 5S rRNA and other stable nuclear and cytoplasmic RNAs. May play a direct role in stabilizing interactions of TFIIIC2 with TFIIIC1

The "GTF3C2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GTF3C2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets